Friday, 12 September 2014

Saxenda® for the treatment of obesity receives positive 14-1 vote in favour of approval from FDA Advisory Committee 

Saxenda®, the intended brand name for liraglutide 3 mg, is a once-daily human GLP-1 analogue for the treatment of obesity (Novo Nordisk)

No comments:

Post a Comment